Syros Pharmaceuticals ^Competitor

Syros Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2011. The company specializes in developing therapies for cancer and genetic diseases by targeting gene regulatory circuits. Syros aims to advance disease treatment through its proprietary platform, which identifies key regulatory regions of the genome to create precision medicines.

The company's pipeline features several small-molecule therapies, including SY-2101, an oral arsenic trioxide for acute promyelocytic leukemia; SY-5609, a selective CDK7 inhibitor for solid tumors and hematologic malignancies; and SY-5007, a RET inhibitor for thyroid and non-small cell lung cancers. Syros collaborates with larger pharmaceutical firms to enhance its drug development efforts and focuses on addressing unmet medical needs in oncology and genetic disorders.